Home » Wenting Zhang, PhD

Wenting Zhang, PhD

Associate Principal

Wenting Zhang, PhD, is an Associate Principal at CBPartners. Wenting supports engagement work across a variety of practices with primary focus on Value, Access, and Pricing.

Connect with Wenting Zhang, PhD

wenting.zhang@cbpartners.com

LinkedIn

Published Articles

What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL

Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.

What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL

The first of two articles investigating market access opportunities in China - CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for rare disease products based on 2020 NRDL update inclusion.

Is the Pricing Discount for Chinese NRDL Inclusion Worth it? NRDL Commercial Impact Assessment

CBPartners Asia Pacific Center of Excellence team have analyzed the dynamics for drug products listed on China’s 2017 NRDL, and subsequent 2018 sales data, to better understand the commercial opportunity within China. Explore the research here.

China’s 2020 NRDL – Standout Features from the Finalized List

There have been several notable standout features in the 2020 NRDL including an update which saw manufacturer applications allowed for the first time compared to prior updates.

ISPOR Asia-Pacific 2020: Comparison of Healthcare Systems and Opportunities for Innovative Drugs Across India, Vietnam, and Indonesia

A research poster that aims to understand how various healthcare system archetypes in APAC markets (e.g., India, Vietnam, and Indonesia) lead to access for high-cost innovative oncology treatments.

ISPOR Asia-Pacific 2020: Dancing with the Dragon – Considerations and Learnings in the 2019 China NRDL Negotiations

A research poster that aims to evaluate the outcomes of the 2019 NRDL negotiations involving PDx inhibitors and DAA products.

ISPOR Asia-Pacific 2020: China’s 2019 NRDL Update – Implications on Global & Local Manufacturer Strategy

A research poster to evaluate 2019 NRDL negotiation outcomes as indicators of potential strategic approaches for multinational and domestic manufacturers to achieve NRDL listing.

2019 NRDL: Insights for Future Pricing Negotiations in China

The 2019 NRDL update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas. CBPartners' blog post examines how these learnings can help shape future NRDL negotiations.

China: There’s a New NRDL in Town

Since the Chinese government brought a deluge of reforms to their pharmaceutical sector in 2018, it is no surprise 2019 is shaping up to be another game-changing year. CBPartners' Asia-Pacific Center of Excellence delivered insights about the evolving NRDL in China, as well as strategic considerations for pharmaceutical manufacturers.

China: Awakening the Pharmaceutical Innovation Giant